Prostate cancer (PCa) is the second most frequent cancer diagnosis in men worldwide and radiation therapy is one of the main treatment options for all disease stages. Due to recent innovations in treatment delivery and medical imaging, PCa radiotherapy has entered the era of high-precision radiation oncology and many patients can be cured while maintaining an excellent quality of life. In parallel, a deeper understanding of tumor biology and integration of mobile health apps facilitate the evolution from a "one size fits all approach" to a personalized and individualized therapy.
The goal of this Research Topic is to concentrate excellent and multidisciplinary scientific contributions on the evolving field of radiotherapy for prostate cancer patients. We welcome authors from all disciplines involved in this topic to submit Original Research, (Systematic) Reviews, and Case Reports from clinical and preclinical standpoints. Economic analysis, cost-effectiveness studies, comparative effectiveness studies, and health services research-related projects are also welcome.
This collection aims to focus on, but is not limited to, the following themes on prostate cancer radiation therapy:
1. Advanced radiation therapy concepts (e.g. focal therapy) for prostate cancer patients
2. Novel prognostic or predictive biomarkers
3. Ultra- or moderately-hypofractionated radiotherapy
4. Metastases-directed therapy in the oligometastatic setting
5. Novel drug interactions
6. Implementation of advanced diagnostic imaging methods
7. Implementation of mobile health apps for treatment personalization
8. Brachytherapy
9. Image-guided and online adaptive radiotherapy
10. Economic analyses including cost-effectiveness studies and health services research-related projects on radiotherapy for prostate cancer
11. Salvage radiation therapy for radio-recurrent prostate cancer
12. Protons and/or carbon-ion therapy for prostate cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Prostate cancer (PCa) is the second most frequent cancer diagnosis in men worldwide and radiation therapy is one of the main treatment options for all disease stages. Due to recent innovations in treatment delivery and medical imaging, PCa radiotherapy has entered the era of high-precision radiation oncology and many patients can be cured while maintaining an excellent quality of life. In parallel, a deeper understanding of tumor biology and integration of mobile health apps facilitate the evolution from a "one size fits all approach" to a personalized and individualized therapy.
The goal of this Research Topic is to concentrate excellent and multidisciplinary scientific contributions on the evolving field of radiotherapy for prostate cancer patients. We welcome authors from all disciplines involved in this topic to submit Original Research, (Systematic) Reviews, and Case Reports from clinical and preclinical standpoints. Economic analysis, cost-effectiveness studies, comparative effectiveness studies, and health services research-related projects are also welcome.
This collection aims to focus on, but is not limited to, the following themes on prostate cancer radiation therapy:
1. Advanced radiation therapy concepts (e.g. focal therapy) for prostate cancer patients
2. Novel prognostic or predictive biomarkers
3. Ultra- or moderately-hypofractionated radiotherapy
4. Metastases-directed therapy in the oligometastatic setting
5. Novel drug interactions
6. Implementation of advanced diagnostic imaging methods
7. Implementation of mobile health apps for treatment personalization
8. Brachytherapy
9. Image-guided and online adaptive radiotherapy
10. Economic analyses including cost-effectiveness studies and health services research-related projects on radiotherapy for prostate cancer
11. Salvage radiation therapy for radio-recurrent prostate cancer
12. Protons and/or carbon-ion therapy for prostate cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
